{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:05:43Z","timestamp":1794575143868,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00198-023-06870-z","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:02:18Z","timestamp":1691748138000},"page":"2027-2045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3129-4326","authenticated-orcid":false,"given":"J.A.","family":"Kanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"\u00c5kesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Azagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Bager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Bischoff-Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Biver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Cauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Center","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chapurlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Crandall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.P.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dawson-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Eisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.M.","family":"Elders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-C.","family":"Gl\u00fcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Goldshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gudnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Hollick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Iki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ish-Shalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Kiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-P.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Koromani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Kotowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Langhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lippuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Merlijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Orwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Pasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rivadeneira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Shiroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Siggeirsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Simonsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sornay-Rendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.A.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Torgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"van Schoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"van Staa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vandenput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"6870_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"6870_CR2","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1359\/jbmr.040917","volume":"19","author":"P Haentjens","year":"2004","unstructured":"Haentjens P, Johnell O, Kanis JA, Bouillon R, Cooper C, Lamraski G, Vanderschuren D, Kauffman J-M, Boonen S (2004) Gender-related differences in short and long-term absolute risk of hip fracture after Colles\u2019 or spine fracture: Colles\u2019 fracture as an early and sensitive marker of skeletal fragility in men. J Bone Miner Res 19:1933\u20131944","journal-title":"J Bone Miner Res"},{"key":"6870_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175\u2013179","journal-title":"Osteoporos Int"},{"key":"6870_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ III, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382","journal-title":"Bone"},{"key":"6870_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00198-014-2875-2","volume":"26","author":"L Hansen","year":"2015","unstructured":"Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harslof T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26:513\u2013519","journal-title":"Osteoporos Int"},{"key":"6870_CR6","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.eclinm.2021.100826","volume":"35","author":"CJ Crandall","year":"2021","unstructured":"Crandall CJ, Hunt RP, LaCroix AZ, Robbins JA, Wactawski-Wende J, Johnson KC, Sattari M, Stone KL, Weitlauf JC, Gure TR, Cauley JA (2021) After the initial fracture in postmenopausal women, where do subsequent fractures occur? EClinicalMedicine 35:100826. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100826","journal-title":"EClinicalMedicine"},{"key":"6870_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, The Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25. https:\/\/doi.org\/10.1007\/s11657-016-0278-z","journal-title":"Arch Osteoporos"},{"key":"6870_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, McCloskey EV, Lorentzon M, Liu E, Vandenput L, McCloskey EV \u2219 National Osteoporosis Guideline Group (2021) An assessment of intervention thresholds for very high risk applied to the NOGG guidelines. A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32: 1951-1960","journal-title":"Osteoporos Int"},{"key":"6870_CR9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864\u20131873","journal-title":"CMAJ"},{"issue":"1","key":"6870_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17(1):58. https:\/\/doi.org\/10.1007\/s11657-022-01061-5 Erratum in: Arch Osteoporos. 2022 May 19;17(1):80","journal-title":"Arch Osteoporos"},{"key":"6870_CR11","doi-asserted-by":"crossref","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25: 2359-2381.","DOI":"10.1007\/s00198-014-2794-2"},{"key":"6870_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320. https:\/\/doi.org\/10.1007\/s11657-012-0109-9","journal-title":"Arch Osteoporos"},{"key":"6870_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"6870_CR14","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102 Erratum in: Osteoporos Int. 2022 Jul 28","journal-title":"Osteoporos Int"},{"key":"6870_CR15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00198-008-0588-0","volume":"19","author":"ND Nguyen","year":"2008","unstructured":"Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431\u20131444","journal-title":"Osteoporos Int"},{"key":"6870_CR16","doi-asserted-by":"publisher","first-page":"b4229","DOI":"10.1136\/bmj.b4229","volume":"339","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of Qfracture Scores. BMJ 339:b4229","journal-title":"BMJ"},{"key":"6870_CR17","volume-title":"Assessment of osteoporosis at the primary health-care level","author":"Kanis JA on behalf of the World Health Organization Scientific Group","year":"2007","unstructured":"Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. WHO Collaborating Centre, University of Sheffield, UK, Technical Report Available at http:\/\/www.shef.ac.uk\/FRAX\/index.htm. Accessed 17 Jan 2023"},{"key":"6870_CR18","volume-title":"Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP\/EWP\/552\/95Rev.2","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2006","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP\/EWP\/552\/95Rev.2. CHMP, London"},{"key":"6870_CR19","unstructured":"National Institute for Health and Care Excellence (2012) NICE clinical guideline 146. In: Osteoporosis: assessing the risk of fragility fracture, London, UK https:\/\/www.nice.org.uk\/guidance\/cg146, Accessed 2 June 2022"},{"key":"6870_CR20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00198-022-06435-6","volume":"33","author":"L Vandenput","year":"2022","unstructured":"Vandenput L, Johansson H, McCloskey EV et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int 33:2103\u20132136. https:\/\/doi.org\/10.1007\/s00198-022-06435-6","journal-title":"Osteoporos Int"},{"key":"6870_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"6870_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00198-019-05274-2","volume":"31","author":"WD Leslie","year":"2020","unstructured":"Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix JM, Johansson H, McCloskey EV, Harvey NC, Kanis JA (2020) Fracture risk following high-trauma versus non-trauma fracture: a registry-based cohort study. Osteoporos Int 31:1059\u20131067","journal-title":"Osteoporos Int"},{"key":"6870_CR23","first-page":"131","volume":"32","author":"NE Breslow","year":"1987","unstructured":"Breslow NE, Day NE (1987) Statistical methods in cancer research, 2 IARC Scientific Publications. Lyon 32:131\u2013135","journal-title":"Lyon"},{"key":"6870_CR24","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2015-3951","volume":"101","author":"K Albertsson-Wikland","year":"2016","unstructured":"Albertsson-Wikland K, Martensson A, Niklasson SLA, Bang P, Martensson A, Dahlgren J, Gustafsson J, Kristrom B, Norgren S, Pehrsson NG, Oden A (2016) Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab 101:2149\u20132159","journal-title":"J Clin Endocrinol Metab"},{"key":"6870_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O\u2019Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"6870_CR26","doi-asserted-by":"publisher","unstructured":"Kline GA, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Leslie WD (2022) General comorbidity indicators contribute to fracture risk independent of FRAX: registry-based cohort study. J Clin Endocrinol Metab:dgac582. https:\/\/doi.org\/10.1210\/clinem\/dgac582 Epub ahead of print","DOI":"10.1210\/clinem\/dgac582"},{"key":"6870_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1532-5415.1994.tb04968.x","volume":"42","author":"KE Ensrud","year":"1994","unstructured":"Ensrud KE, Nevitt MC, Yunis C, Cauley JA, Seeley DG, Fox KM, Cummings SR (1994) Correlates of impaired function in older women. J Am Geriatr Soc 42:481\u2013489","journal-title":"J Am Geriatr Soc"},{"key":"6870_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530. https:\/\/doi.org\/10.1002\/jbmr.2176 Erratum in: J Bone Miner Res 2017 Nov;32(11):2319","journal-title":"J Bone Miner Res"},{"key":"6870_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","volume":"78","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Gl\u00fcer CC, Binkley N, McCloskey EV, Brandi M-L, Cooper C, Kendler D, Lamy O, Laslop A, Camargos B, Reginster J-Y, Rizzoli R, Kanis JA (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. A consensus report of a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Working Group. Bone 78:216\u2013224","journal-title":"Bone"},{"issue":"1","key":"6870_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","volume":"7","author":"EJ Samelson","year":"2019","unstructured":"Samelson EJ, Broe KE, Xu H, Yang L, Boyd S, Biver E, Szulc P, Adachi J, Amin S, Atkinson E, Berger C, Burt L, Chapurlat R, Chevalley T, Ferrari S, Goltzman D, Hanley DA, Hannan MT, Khosla S et al (2019) Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol 7(1):34\u201343. https:\/\/doi.org\/10.1016\/S2213-8587(18)30308-5 Erratum in: Lancet Diabetes Endocrinol. 2019 Jan;7(1):e1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jun;7(6):e18","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6870_CR31","doi-asserted-by":"crossref","unstructured":"Dempster DW 92000  The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 15:20\u201323","DOI":"10.1359\/jbmr.2000.15.1.20"},{"key":"6870_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00198-005-2035-9","volume":"17","author":"S Viguet-Carrin","year":"2006","unstructured":"Viguet-Carrin S, Garnero P, Delmas PD (2006) The role of collagen in bone strength. Osteoporos Int 17:319\u2013336","journal-title":"Osteoporos Int"},{"key":"6870_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bone.2018.10.010","volume":"120","author":"DB Burr","year":"2019","unstructured":"Burr DB (2019) Changes in bone matrix properties with aging. Bone 120:85\u201393. https:\/\/doi.org\/10.1016\/j.bone.2018.10.010","journal-title":"Bone"},{"key":"6870_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583\u20131587","journal-title":"J Clin Endocrinol Metab"},{"key":"6870_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00198-021-06252-3","volume":"33","author":"A Agarwal","year":"2022","unstructured":"Agarwal A, Leslie WD, Nguyen TV, Morin SN, Lix LM, Eisman JA (2022) Predictive performance of the Garvan Fracture Risk Calculator: a registry-based cohort study. Osteoporos Int 33:541\u2013548","journal-title":"Osteoporos Int"},{"key":"6870_CR36","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-022-06550-4","volume":"33","author":"JA Kanis","year":"2022","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2022) Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures. Osteoporos Int 33:2507\u20132515","journal-title":"Osteoporos Int"},{"key":"6870_CR37","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","volume":"14","author":"DM Black","year":"1999","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821\u2013828","journal-title":"J Bone Miner Res"},{"key":"6870_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00198-006-0306-8","volume":"18","author":"ES Siris","year":"2007","unstructured":"Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH (2007) Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18:761\u2013770","journal-title":"Osteoporos Int"},{"key":"6870_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522\u2013532","journal-title":"Bone"},{"key":"6870_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S8756-3282(03)00248-5","volume":"33","author":"M Lunt","year":"2003","unstructured":"Lunt M, O\u2019Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, Silman AJ, European Prospective Osteoporosis Study Group (2003) Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone 33:505\u2013513","journal-title":"Bone"},{"key":"6870_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s001980170131","volume":"12","author":"O Johnell","year":"2001","unstructured":"Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207\u2013214","journal-title":"Osteoporos Int"},{"key":"6870_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/jbmr.35","volume":"25","author":"LM Giangregorio","year":"2010","unstructured":"Giangregorio LM, Leslie WD (2010) Manitoba bone density program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400\u20131405","journal-title":"J Bone Miner Res"},{"key":"6870_CR43","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00198-006-0125-y","volume":"17","author":"T Nymark","year":"2006","unstructured":"Nymark T, Lauritsen JM, Ovesen O, Rock ND, Jeune B (2006) Short timeframe from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353\u20131357","journal-title":"Osteoporos Int"},{"key":"6870_CR44","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A, Harvey NC, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Borgstr\u00f6m F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757","journal-title":"Osteoporos Int"},{"key":"6870_CR45","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00198-020-05803-4","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu M, Vandenput L, McCloskey E (2021) The effect on subsequent fracture risk of age, sex and prior fracture site by recency of prior fracture. Osteoporos Int 32:1547\u20131555","journal-title":"Osteoporos Int"},{"key":"6870_CR46","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-022-06387-x","volume":"33","author":"L Johansson","year":"2021","unstructured":"Johansson L, Johansson H, Harvey NC, Liu E, Vandenput L, McCloskey E, Kanis JA, Lorentzon M (2021) Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporos Int 33:1725\u20131738","journal-title":"Osteoporos Int"},{"key":"6870_CR47","unstructured":"McCloskey EV (2013) FRAXplus \u2013 post hoc exploration of impact of additional risk factor information on FRAX probability calculations. Aging Clin Exp Res 35 (Suppl 1) in press"},{"key":"6870_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","volume":"90","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX(\u00ae) with and without bone mineral density. Calcif Tissue Int 90:1\u201313","journal-title":"Calcif Tissue Int"},{"key":"6870_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06870-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T04:02:26Z","timestamp":1700020946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6870"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06870-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield. Participant data will be stored in coded, de-identified form. Only summary statistics and aggregate data will be published, not allowing for identification of individual study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"J.A. Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases. E.V. McCloskey, W.D. Leslie, M. Lorentzon, N.C. Harvey, E. Liu, L. Vandenput, and H. Johansson are members of the FRAX team. J.A. Kanis, N.C. Harvey, and E.V. McCloskey are members of the advisory body to the National Osteoporosis Guideline Group. J.A. Kanis reports no additional competing interests. K.E. \u00c5kesson has no financial interest related to FRAX; chaired the National SALAR Group for Person-Centered Care Pathway Osteoporosis. F.A. Anderson led the team that developed GLOW, while director of the Center for Outcomes Research at the University of Massachusetts Medical School; he has no financial interest in FRAX. R. Azagra has received funding for research from Instituto Carlos III of Spanish Ministry of Health, IDIAP Jordi Gol of Catalan Government, and from Scientific Societies SEMFYC and SEIOMM. C.L. Bager is employed at Nordic Bioscience and owns stock in Nordic Bioscience. She declares no competing interests in relation to this work. H.A. Bischoff-Ferrari has no financial interest in FRAX. For the DO-HEALTH trial cohort, Prof. Bischoff-Ferrari reports independent and investigator-initiated grants from European Commission Framework 7 Research Program, from the University of Zurich, from NESTEC, from Pfizer Consumer Healthcare, from Streuli Pharma, plus non-financial support from DNP. For the study cohort extension, she reports independent and investigator-initiated grants from Pfizer and from Vifor. Further, Prof. Bischoff-Ferrari reports non-financial support from Roche Diagnostics and personal fees from Wild, Sandoz, Pfizer, Vifor, Mylan, Roche, Meda Pharma, outside the submitted work with regard to speaker fees and travel fees. J.R. Center has received honoraria for speaking at educational meetings and for advisory boards from Amgen and honoraria for an advisory board from Bayer. R. Chapurlat has no financial interest in FRAX. He has received grant funding from Amgen, UCB, Chugai, MSD, Mylan and Medac. He has received honoraria from Amgen, UCB, Chugai, Galapagos, Biocon, Abbvie, Haoma Medica, Pfizer, Amolyt, MSD, Lilly, BMS, Novartis, Arrow, PKMed, Kyowa-Kirin, and Sanofi. C. Christiansen owns stock in Nordic Bioscience. He declares no competing interests in relation to this work. C. Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda. and UCB. A. Diez-Perez reports personal fees from Amgen, Lilly, Theramex and grants from Instituto Carlos III and owns shares of Active Life Scientific, all outside the submitted work. J.A. Eisman declares consulting and research support from Actavis, Amgen, Aspen, Lilly, Merck Sharp and Dohme, Novartis, Sanofi-Aventis, Servier, and Theramex. P.J.M. Elders has no financial interest in FRAX. P.J.M. Elders reports support for the SOS study by Stichting Achmea Gezondheidszorg, Achmea, and VGZ zorgverzekeraar. Additional support was given by the stichting Artsenlaboratorium en Trombosedienst. Outside the submitted work, she did receive independent investigator-driven grants by Zonmw, the Netherlands; de Hartstichting, the Netherlands; the European foundation for the study of Diabetes, Amgen, the Netherlands; TEVA, the Netherlands; and Takeda, the Netherlands. Claus-C. Gl\u00fcer reports honoraria and research support from AgNovos, Amgen, Osteolabs, and UCB unrelated to this work. N.C. Harvey has received consultancy\/lecture fees\/honoraria\/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare, and Internis Pharma. D.P. Kiel has no financial interest in FRAX but has received support for his work in the Framingham Study over the past 30 years by the National Institutes of Health, Astra Zeneca, Merck, Amgen, and Radius Health. MA Kotowicz has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia. He has served on advisory boards for Amgen Australia, Novartic, and Eli Lilly\u2014all unrelated to this work, and is the Director of the Geelong Bone Densitometry Service. M. Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health, all outside the presented work. E.V. McCloskey has received consultancy\/lecture fees\/grant funding\/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott, and I3 Innovus. C. Ohlsson is listed as a coinventor on two patent applications regarding probiotics in osteoporosis treatment. E.S. Orwoll reports consulting fees from Amgen, Biocon, Radius, and Bayer, and research support from Mereo. J.A. Pasco has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia, all unrelated to this work. K.M.A. Swart is an employee of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. N.C. Wright sits on the Board of Trustee of the US Bone Health and Osteoporosis Foundation and has received consulting fees from Radius and ArgenX. M.C. Zillikens has received honoraria in the past for lectures or advice from Alexion, Amgen, Eli Lilly, Kyowa Kirin, Shire, and UCB, unrelated to the current work. M. Zwart has received research funding from national societies (SEMFYC and SEIOMM). C. Beaudart, E. Biver, O. Bruy\u00e8re, J.A. Cauley, C.J. Crandall, S.R. Cummings, J.A.P. da Silva, B. Dawson-Huges, A.B. Dufour, S. Ferrari, Y. Fujita, S. Fujiwara, I. Goldshtein, D. Goltzman, V. Gudnason, J. Hall, D. Hans, M. Hoff, R.J. Hollick, M. Huisman, M. Iki, S. Ish-Shalom, H. Johansson, G. Jones, M.K. Karlsson, S. Khosla, W.-P. Koh, F. Koromani, H. Kr\u00f6ger, T. Kwok, O. Lamy, A. Langhammer, B. Larijani, W.D. Leslie, K. Lippuner, E. Liu, D. Mellstr\u00f6m, T. Merlijn, A. Nordstr\u00f6m, P. Nordstr\u00f6m, T.W. O\u2019Neill, B. Obermayer-Pietsch, F. Rivadeneira, A.-M. Schott, E.J. Shiroma, K. Sigeirsdottir, E.M. Simonsick, E. Sornay-Rendu, R. Sund, K.M.A. Swart, P. Szulc, J. Tamaki, D.J. Torgerson, L. Vandenput, N.M. van Schoor, T.P. van Staa, J. Vila, N.J. Wareham, and N. Yoshimura declare no competing interests in relation to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}